Sign In
Buy IONS
$73.82
+0.85 (+1.16%)
At Close: Jun 03, 2026
Ionis (IONS) Q1 Earnings & Sales Beat Estimates, Stock Rises
03:45pm, Thursday, 05'th May 2022 Zacks Investment Research
Ionis (IONS) incurs a narrower-than-expected loss in Q1. Its sales also come ahead of estimates. Stock moves up in response to the results.
Ionis Pharmaceuticals, Inc. (IONS) CEO Brett Monia on Q1 2022 Results - Earnings Call Transcript
02:50pm, Wednesday, 04'th May 2022
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) Q1 2022 Earnings Conference Call May 4, 2022 11:30 AM ET Company Participants Brett Monia - Founder, CEO & Director Elizabeth Hougen - EVP, Finance & CFO Eug
Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates
12:15pm, Wednesday, 04'th May 2022 Zacks Investment Research
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 32.35% and 9.90%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates
09:47am, Wednesday, 04'th May 2022
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 32.35% and 9.90%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Should You Buy?
07:03pm, Wednesday, 27'th Apr 2022 Zacks Investment Research
Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
7 Potential Biotech Stocks Buyout Targets in 2022
08:10am, Thursday, 21'st Apr 2022
Big biopharma companies usually rely on M&A to get immediate access to a new class of drug or technology, fill in the gap in their pipeline and compensate for revenue loss from patent expiration of bl
Ionis to hold first quarter 2022 financial results webcast
07:05am, Wednesday, 20'th Apr 2022
Webcast scheduled for Wednesday, May 4 at 11:30 a.m. Eastern Time CARLSBAD, Calif.
Hold Ionis Pharmaceuticals as the share price moved to find a $60 valuation
10:23pm, Tuesday, 05'th Apr 2022 Invezz
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is on a bullish streak that began three weeks ago. Last week, the brand reported success in research on a cholesterol drug that it is developing in partnershi
Hold Ionis Pharmaceuticals as the share price moved to find a $60 valuation
06:23pm, Tuesday, 05'th Apr 2022
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is on a bullish streak that began three weeks ago. Last week, the brand reported success in research on a cholesterol drug that it is developing in partnershi
Expert Ratings For Ionis Pharmaceuticals
01:14pm, Friday, 01'st Apr 2022 Benzinga
Within the last quarter, Ionis Pharmaceuticals (NASDAQ:IONS) has observed the following analyst ratings:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
1
0
2
1
1
Biogen (BIIB), Ionis to End Early-Stage ALS Candidate Development
05:03pm, Tuesday, 29'th Mar 2022 Zacks Investment Research
Biogen (BIIB) & partner Ionis (IONS) to terminate the development of their antisense ALS candidate, as the drug failed to show any clinical benefit in an early-stage study for C9orf72-associated ALS.
Biogen (BIIB), Ionis to End Early-Stage ALS Candidate Development
02:18pm, Tuesday, 29'th Mar 2022
Biogen (BIIB) & partner Ionis (IONS) to terminate the development of their antisense ALS candidate, as the drug failed to show any clinical benefit in an early-stage study for C9orf72-associated ALS.
Ionis-Biogen Partnered Amyotrophic Lateral Sclerosis Trial Disappoints
10:15am, Monday, 28'th Mar 2022
Biogen Inc (NASDAQ: BIIB) and Ionis Pharmaceuticals Inc (NASDAQ: IONS) have announced topline results from the Phase 1 study of BIIB078 (IONIS-C9Rx) for C9orf72-associated amyotrophic lateral scl
Ionis Pharmaceuticals: Finding Financial Value In Biotech Research
06:30am, Sunday, 27'th Mar 2022
Ionis Pharmaceuticals specializes in developing RNA-targeted therapeutics - one of the fastest-growing research areas in the biotech sector.
This group of stocks is flagging a rebound, and that's good news for the S&P 500, says technical analyst
01:05pm, Tuesday, 22'nd Mar 2022 MarketWatch
Where is the market going after last week's rally? Our call of the day from MKM's chief strategist is looking at healthy signals from the healthcare sector.
